add or edit History, Causes & risk factors, Pathophysiology, Signs and symptoms, Complications, Diagnosis, Prophylaxis, Current research, Treatment options, Conventional marketed formulations, Novel m

Literature Landscape

The literature on endometriosis exhibits a shifting focus from broad diagnostic standards and epidemiological risk to targeted molecular management. Research is currently structured across five primary thematic clusters: Endometriosis Medical Management (C1, stable momentum), Endometriosis Genetics and Metabolism (C2, declining), Endometriosis Diagnosis and Therapy (C3, waning), Endometriosis Epidemiology and Risk (C4, waning), and ARID1A Mutations in Ovarian Carcinoma (C5, stable). High-degree hubs in the network, such as systematic reviews on NSAIDs for pain (PMID: 28114727) and oxidative stress biomarkers (PMID: 22791380), anchor the field's clinical consensus. Bridging papers, notably those addressing the spectrum of adolescent symptoms (PMID: 9391902) and epigenetic mechanisms (PMID: 19651637), integrate clinical observations with emerging metabolic and genetic insights.

History

Clinical descriptions of symptoms resembling endometriosis appear in medical records dating back approximately 4000 years (PMID: 32412587). Modern pathological classification began with Karl von Rokitansky in 1860, followed by the morphological definitions provided by Thomas Cullen in 1908 and 1920 (PMID: 32412587). The term "endometriosis" and the influential "retrograde menstruation theory" were formally proposed by John Sampson in 1927 (PMID: 32412587). Sampson also described the dissemination of endometrial tissue via venous circulation, suggesting a metastatic-like mechanism for certain disease presentations (PMID: 19969738). The induction of a "pseudo-pregnancy" state for therapeutic control was established in the late 1950s (PMID: 32412587).

Causes & risk factors

The etiology of endometriosis is considered multifactorial, involving retrograde menstruation, coelomic metaplasia, and stem cell theories (PMID: 34104002). Retrograde menstruation remains the cornerstone theory for pelvic tissue transplantation (PMID: 22819144). Risk is elevated in individuals with increased exposure to menstruation, including those with early menarche, short cycles, and heavy flow (PMID: 29920379; PMID: 11949940). Heritability is estimated at approximately 51%, with a six-fold increase in risk for first-degree relatives of affected women (PMID: 36387918; PMID: 22819144). Environmental factors, such as in utero exposure to diethylstilbestrol (DES) or organochlorine chemicals like TCDD, are associated with increased susceptibility (PMID: 19196878; PMID: 30530163). Epidemiological data also indicate that low birthweight (<2.5 kg) is a significant risk factor for a subsequent diagnosis (PMID: 32141508).

Pathophysiology

Endometriosis is characterized by a "pre-metastatic" phenotype involving sustained inflammation, estrogen dependence, and progesterone resistance (PMID: 28423456). Progesterone resistance stems from a deficiency in progesterone receptor B (PR-B), often due to epigenetic hypermethylation of the PGR gene promoter induced by inflammatory mediators (PMID: 32412587; PMID: 36387918). Estrogen dependency is driven by increased aromatase expression and decreased 17β-hydroxysteroid dehydrogenase (17β-HSD) type 2 in ectopic lesions, creating a high-estradiol local environment that stimulates PGE2 production (PMID: 22819144; PMID: 32385745). Chronic inflammation results in progressive fibrosis and extracellular matrix remodeling mediated by myofibroblast differentiation (FMT) and epithelial-to-mesenchymal transition (EMT) (PMID: 39067455). This process is frequently associated with "tissue injury and repair" (TIAR) mechanisms and iron-mediated oxidative stress in the peritoneal fluid and ovarian follicles (PMID: 19644696; PMID: 37638130).

Signs and symptoms

Clinical presentations typically include cyclic and non-cyclic chronic pelvic pain, dysmenorrhea, deep dyspareunia, and dysuria (PMID: 32212520; PMID: 35350465). Other symptoms associated with pelvic or deep endometriosis include dyschezia, painful rectal bleeding, hematuria, and fatigue (PMID: 35350465). Approximately 30-50% of women with endometriosis experience infertility, often due to distorted pelvic anatomy and an altered peritoneal environment (PMID: 36387918; PMID: 32212520). Adolescents often present with acyclic pain or symptoms non-responsive to first-line oral contraceptives and NSAIDs (PMID: 9391902).

Complications

Complications include significant organ damage and anatomical distortion due to progressive fibrosis and adhesions (PMID: 39067455; PMID: 36387918). Endometriosis is associated with an elevated risk of obstetric complications, such as first-trimester miscarriage, ectopic pregnancy, preterm birth, and placenta previa (PMID: 35350465; PMID: 30239732). A rare but critical complication is malignant transformation into endometriosis-associated ovarian cancer (EAOC), particularly clear cell and endometrioid carcinomas (PMID: 32385745; PMID: 24518590). Individuals with early-diagnosed and long-standing disease have elevated standardized incidence ratios for ovarian and endocrine tumors (PMID: 19196878).

Diagnosis

Diagnosis has transitioned from surgical gold-standard reliance toward an "imaging-first" protocol using transvaginal ultrasound (TVS) or MRI (PMID: 35350465; PMID: 30625295). TVS is highly accurate for mapping deep endometriosis (DIE) to sites such as the rectovaginal septum and pouch of Douglas, though its sensitivity for superficial peritoneal lesions is limited (PMID: 26919512; PMID: 26051099). Despite these advancements, diagnostic delay remains high, averaging 6.7 to 10 years globally (PMID: 39373298; PMID: 30625295). Serum CA-125 measurement has limited diagnostic performance for grade I/II disease but may identify subgroups likely to benefit from early laparoscopy (PMID: 9848302).

Prophylaxis

Current evidence does not support specific primary prevention advice (PMID: 29920379). Secondary prevention focuses on post-operative hormonal suppression (PMID: 33020832). Initiating hormonal suppression within 6 weeks post-surgery significantly reduces the relative risk of radiological and clinical disease recurrence (PMID: 33020832; PMID: 35350465).

Current research

Current research explores non-hormonal targets such as the NLRP3 inflammasome, which contributes to IL-1β activation and lesion progression; in murine models, the NLRP3 inhibitor MCC950 significantly reduced OE lesion size (PMID: 35351143). Investigations into the gut microbiome suggest that antibiotic therapy with metronidazole can reduce lesion growth and inflammation (PMID: 31037294). Other emerging areas target signaling pathways including MAPK/ERK, PI3K/Akt/mTOR, and Wnt/β-catenin as alternatives to traditional suppressive therapies (PMID: 33948974). Extracellular vesicles are also being explored for their diagnostic and therapeutic role in immunomodulation and fibrogenesis (PMID: 36544197).

Treatment options

Management depends on the functional impact of the disease (PMID: 29920379). Options include medical suppression, surgical excision, and assisted reproductive technologies (ART) (PMID: 35350465). 2022 ESHRE guidelines recommend combined hormonal contraceptives or progestogens as first-line medical therapy (PMID: 35350465). GnRH agonists are recommended as second-line treatment, ideally combined with add-back therapy to mitigate bone mineral density (BMD) loss (PMID: 35350465). Surgery is indicated when medical therapy is insufficient or for deep infiltrating disease affecting the bowel or urinary tract (PMID: 35350465; PMID: 29920379).

Conventional marketed formulations

Conventional hormonal therapies include the 52mg levonorgestrel-releasing IUS (PMID: 33948974; PMID: 29920379). Aromatase inhibitors (e.g., anastrozole) are used off-label for refractory cases, typically in combination with a progestin or GnRH agonist (PMID: 35350465; PMID: 16084868). Danazol, once a primary therapy, is now rarely used due to significant androgenic side effects (PMID: 32412587).

Novel marketed formulations

Novel oral GnRH receptor antagonists allow for dose-dependent suppression of estradiol without the flare-up effect of agonists (PMID: 28525302; PMID: 38592603). Elagolix is approved at 150 mg once daily or 200 mg twice daily for moderate-to-severe pain (PMID: 28525302). Relugolix combination therapy (40 mg relugolix with 1.0 mg estradiol and 0.5 mg norethindrone acetate) has been shown to sustain efficacy and maintain BMD for up to 2 years (PMID: 38592603). Linzagolix administered at 200 mg with add-back therapy significantly reduces dysmenorrhea and non-menstrual pelvic pain (PMID: 38648863).

Conclusion

Endometriosis remains a complex chronic condition with significant diagnostic delays and high recurrence rates following conventional treatment. Pathophysiological hallmarks such as PR-B deficiency and iron-mediated oxidative stress highlight major limitations in current hormonal therapies. While oral GnRH antagonists represent a significant therapeutic advancement, there is an ongoing need for non-hormonal strategies that address fibrogenesis and inflammation without compromising fertility. Future diagnostics focusing on biomarkers such as circulating microRNAs and imaging advances like elastosonography are essential for earlier intervention and improved patient trajectories.

Research notebook

What are the current established and emerging theories for the etiology and pathophysiology of endometriosis (e.g., retrograde menstruation, coelomic metaplasia, stem cell theory)?

Endometriosis pathogenesis is primarily explained by several complementary theories, including retrograde menstruation, coelomic metaplasia, and the stem cell theory, often characterized by a "pre-metastatic" phenotype involving inflammation and progesterone resistance.

Status: verified • Confidence: medium

• Endometriosis is defined by the presence of endometrium-like tissue outside the uterus, most commonly on the pelvic peritoneum and ovaries, and is associated with chronic pelvic pain and infertility. (PMID 32212520, abstract)
• Retrograde menstruation, originally proposed by Sampson in the 1920s, remains the most widely accepted mechanism for the transplantation of endometrial tissue into the peritoneal cavity. (PMID 22819144, abstract)
• Sampson's seminal 1927 work described the dissemination of endometrial tissue via venous circulation, suggesting a metastatic-like spread for certain types of endometriosis. (PMID 19969738, abstract)
• Progesterone resistance, characterized by a lack of response to endogenous or exogenous progesterone, is a hallmark of endometriotic lesions and contributes to leur survival and growth. (PMID 28423456, abstract)
• Contemporary theories integrate retrograde menstruation with coelomic metaplasia (transformation of peritoneal cells) and the involvement of bone marrow-derived stem cells in the development of lesions. (PMID 34104002, abstract)

What are the primary risk factors, clinical presentations (signs and symptoms), and common complications associated with endometriosis?

Endometriosis presents with diverse clinical symptoms, most notably chronic pelvic pain, dysmenorrhea, and infertility, and can lead to complications such as organ damage, fibrosis, and a small but significant risk of malignant transformation.

Status: verified • Confidence: medium

• Clinical presentations typically include cyclic pelvic pain (dysmenorrhea), noncyclic chronic pain, dyspareunia, and dyschezia, often with a significant delay in diagnosis. (PMID 32212520, abstract)
• Endometriosis is a major cause of female infertility, affecting approximately 30-50% of women with the condition through mechanisms such as distorted pelvic anatomy and altered peritoneal environment. (PMID 36387918, abstract)
• Chronic inflammation in endometriosis leads to progressive fibrosis, which is responsible for scarring, organ adhesions, and persistent pain. (PMID 39067455, abstract)
• Pregnancy in women with endometriosis may be associated with increased risks of spontaneous hemoperitoneum and complications like preterm birth and placenta previa. (PMID 26450609, abstract)
• While generally benign, endometriosis-associated ovarian cancer (EAOC), particularly clear cell and endometrioid types, represents a rare but critical complication of the disease. (PMID 32385745, abstract)

What is the current standard for diagnosing endometriosis (e.g., imaging, biomarkers, surgical confirmation)?

Diagnosis of endometriosis has transitioned from a reliance on surgical laparoscopy to an "imaging-first" approach using transvaginal ultrasound and MRI, although diagnostic delays remain common.

Status: verified • Confidence: medium

• The 2022 ESHRE guidelines state that laparoscopy is no longer the gold standard diagnostic tool and recommend transvaginal ultrasound or MRI as primary diagnostic modalities. (PMID 35350465, abstract)
• Diagnostic delay for endometriosis often averages 7-10 years globally, highlighting the need for increased clinical suspicion and improved non-invasive diagnostic tools. (PMID 30625295, abstract)
• Transvaginal ultrasound (TVS) is highly accurate for diagnosing endometriomas and deep endometriosis, though its sensitivity for superficial peritoneal lesions remains limited. (PMID 26919512, abstract)
• Regional variations and healthcare disparities contribute significantly to the prolonged time to diagnosis for many women with pelvic pain symptoms. (PMID 39373298, abstract)

What are the established conventional treatments (medical and surgical) and currently marketed formulations?

Established treatments for endometriosis focus on hormonal suppression and surgical excision, but both carry high recurrence rates and limitations for patients desiring pregnancy.

Status: verified • Confidence: medium

• Conventional medical therapies include combined oral contraceptives, progestogens, and GnRH agonists, which aim to induce a hypoestrogenic state and suppress lesion growth. (PMID 35350465, abstract)
• Elagolix, an oral GnRH receptor antagonist, has been shown to significantly reduce dysmenorrhea and nonmenstrual pelvic pain in women with moderate-to-severe endometriosis. (PMID 28525302, abstract)
• NSAIDs are commonly used for symptom management, although systematic reviews suggest limited high-quality evidence for their superior efficacy over placebo in endometriosis-specific pain. (PMID 28114727, abstract)
• Progestogens are a mainstay of treatment, but their effectiveness is often limited by progesterone resistance in endometriotic tissue, leading to treatment failure in some patients. (PMID 32412587, abstract)
• Post-operative hormonal suppression can reduce the risk of disease recurrence, but recurrence of pain remains a significant challenge after stopping therapy. (PMID 33020832, abstract)

What is the historical evolution of the understanding of endometriosis and its initial clinical descriptions?

The historical understanding of endometriosis has evolved from early pathological descriptions in the 19th century to the formulation of the influential transplantation theory by John Sampson in the 1920s.

Status: verified • Confidence: medium

• John Sampson's seminal 1927 paper introduced the theory of "menstrual dissemination" or retrograde menstruation, suggesting that endometrial tissue could be transplanted to various locations via the venous circulation and peritoneal cavity. (PMID 19969738, abstract)
• Historical perspectives on endometriosis etiology have been dominated by Sampson's retrograde menstruation theory since the 1920s, which remains the cornerstone of modern understanding despite the addition of newer theories like coelomic metaplasia. (PMID 34104002, abstract)

What are the novel therapeutic strategies, including emerging drug formulations and future research directions (e.g., immunotherapy, non-hormonal targets)?

Novel therapeutic strategies for endometriosis are expanding to include second-generation oral GnRH antagonists, such as relugolix and linzagolix, as well as non-hormonal targets involving inflammatory pathways and the microbiome.

Status: verified • Confidence: medium

• Relugolix combination therapy (relugolix, estradiol, and norethisterone acetate) has been recently approved and reviewed for the effective management of moderate-to-severe endometriosis-associated pain. (PMID 38592603, abstract)
• The Phase 3 EDELWEISS 3 study demonstrated that linzagolix, a new oral GnRH antagonist, significantly reduced dysmenorrhea and non-menstrual pelvic pain compared to placebo. (PMID 38648863, abstract)
• Preclinical studies have identified the NLRP3 inflammasome as a potential non-hormonal therapeutic target for reducing the growth and inflammation of endometriotic lesions. (PMID 35351143, abstract)
• Emerging research is targeting various signaling pathways, including those involving MAPK/ERK and PI3K/Akt, as potential non-hormonal alternatives to traditional suppressive therapies. (PMID 33948974, abstract)
• The gut microbiome has been implicated in disease progression, with metronidazole treatment showing potential for reducing lesion size and inflammation in mouse models of endometriosis. (PMID 31037294, abstract)